

## Purification of Recombinant Human Alpha1-Antitrypsin From Transgenic Milk Using CHT™ Ceramic Hydroxyapatite

Samuel G Franklin, PhD, Bio-Rad Laboratories, Hercules, CA 94547 USA

### Introduction

Alpha1-antitrypsin ( $\alpha$ 1-AT) is the principal serum inhibitor of proteases such as elastase. Deficiency of  $\alpha$ 1-AT causes chronic emphysema due to uncontrolled elastase activity released from lung neutrophils. Elastase degrades elastin and collagen, producing the fibrosis and stiffening of tissues that are characteristic of the disease. An estimated 75,000 to 150,000 individuals in the US have hereditary  $\alpha$ 1-AT deficiency, 20,000 to 40,000 of whom develop emphysema. The dose requirement for  $\alpha$ 1-AT protein replacement therapy is about 120 g/patient/yr and, although plasma-derived products exist, manufacture of enough of these products is not possible. The advent of transgenic technology has made it possible to express  $\alpha$ 1-AT in sheep and goat's milk at 1–35 g/L, and 3 L/day/goat is obtained (Wright et al. 1991). Thus, assuming 20 g/L are expressed, some 200 goats could supply US requirements of about 4,000 kg/yr.

Human  $\alpha$ 1-AT is a 52 kD glycoprotein consisting of 394 residues. It is relatively fragile, being susceptible to heat denaturation and methionine oxidation, and aggregates progressively at pHs above and below 7.5 (Vemuri et al. 1993). Various techniques including ion exchange, hydrophobic interaction, and immobilized metal affinity chromatography (IMAC) have been used to purify  $\alpha$ 1-AT, but the number of steps and relatively harsh elution conditions have led to destabilization of the bulk protein. Purification from milk is additionally challenging because some goat  $\alpha$ 1-AT (about 1%) is present, and two major milk proteins,  $\alpha$ -lactalbumin and  $\beta$ -lactoglobulin, have isoelectric points and titration curves very similar to  $\alpha$ 1-AT. In this note, we describe the development of a simple, gentle process for the purification of  $\alpha$ 1-AT from clarified goat's milk, using CHT™ ceramic hydroxyapatite.

### Methods and Results

Goat's milk clarified by ultrafiltration was equilibrated with 10 mM sodium phosphate buffer, pH 7.0 (buffer A) by dialysis or desalting column. It was applied directly to a

2.0 ml Bio-Scale™ ceramic hydroxyapatite Type I column (CHT-I, catalog #751-0021) equilibrated with buffer A. Elution was accomplished by a shallow linear gradient from 10 to 400 mM sodium phosphate buffer, pH 7.0 (buffer B). Figure 1 shows the elution profile from this column. SDS-PAGE analysis (Figure 2) indicated that the  $\alpha$ -lactalbumin




Fig. 1. Purification of  $\alpha$ 1-AT on CHT-I. Column, 7 x 52 mm; load, 5.0 ml. Buffer A, 10 mM sodium phosphate, pH 7.0; buffer B: 400 mM sodium phosphate, pH 7.0. Gradient, 0–5% B and 5–30% B in 5 column volumes (CV) each, 30–100% B in 10 CV. Flow rate, 2.5 ml/min. Fractions were 1.5 ml, pooled as follows: pooled fraction I = run fractions 12–17, II = 23–24, III = 42–49, IV = 49–50, V = 51–53, VI = 54–58, VII = 69–71, VIII = 74–77. Green bar indicates where  $\alpha$ 1-AT eluted.




Fig. 2. SDS-PAGE analysis of pooled fractions from Figure 1. Lane 1, MW markers (203, 118, 86, 51.6, 34.1, 29, 19.2, 7.5 kD); lane 2, load; lanes 3–10, pooled fractions I–VIII. Protein migration positions were identified by running standards (not shown). Gel was 15% acrylamide and stain was Coomassie Brilliant Blue R-250.

emerged in the unbound fraction, while the caseins and  $\beta$ -lactoglobulin were tightly bound to the column and emerged at the end of the gradient. The central peak (Figure 1, green bar) contained the  $\alpha$ 1-AT. The minor component above the  $\alpha$ 1-AT (Figure 2, lanes 5 and 6) may be due to microheterogeneity or may be the goat species. Because of the presence of this trace component, a two-step procedure was evaluated.

A capture step using immobilized copper affinity chromatography provided approximately 50% pure  $\alpha$ 1-AT (not shown). The product from this column was equilibrated with Buffer A and applied to the CHT-I column under conditions identical to those described above. The profile from this column (Figure 3) was similar to that generated by clarified milk (Figure 1) except that the large peak near the end of the gradient, shown previously to contain the  $\beta$ -lactoglobulin, was absent. This was confirmed by SDS-PAGE (Figure 4), which also showed that the  $\alpha$ 1-AT peak (Figure 3, green bar) was now homogeneous. Reversed phase HPLC analysis of the fractions indicated that pooled fractions III-V were 83–98% pure.

### Discussion

This two-step process was shown to provide highly purified  $\alpha$ 1-AT. Although an additional polishing step may be required for viral clearance and pharmaceutical requirements, CHT-I has been shown to complement IMAC by providing a simple, gentle alternative to conventional chromatography. The rather large difference in retention times for  $\alpha$ 1-AT, goat  $\beta$ -lactalbumin, and goat  $\beta$ -lactoglobulin, which have very similar isoelectric points (5.27, 5.16, and 4.77, respectively), is a good illustration of the unique separation capabilities afforded by CHT-I.

### References

Vemuri S et al., Formulation and stability of recombinant alpha1-antitrypsin, *Pharm Biotechnol* 5, 263–286 (1993)

Wright T et al., High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep, *Biotechnology* 9, 830-834 (1991)

### Acknowledgement

Transgenic goat's milk and the copper affinity chromatography fraction containing  $\alpha$ 1-AT were provided by Genzyme Transgenics Corporation.

Coomassie is a trademark of Imperial Chemical Industries.

Information in this tech note is current as of the date of writing (1999) and not necessarily the date of this revision or reprinting (Rev B, 2002).




Fig. 3. Purification of copper chelate product on CHT-I. Load, 5.0 ml. Conditions were as in Figure 1. Pooled fraction I = run fractions 13–17, II = 20–21, III = 23–24, IV = 40–46, V = 49–58, VI = 63–65, VII = 68–71. Green bar indicates where  $\alpha$ 1-AT eluted.




Fig. 4. SDS-PAGE analysis of pooled fractions from Figure 3. Lane 1, HSA; lane 2,  $\alpha$ 1-AT (Sigma); lane 3, load; lanes 4–10, pooled fractions I–VII. Conditions were as in Figure 2.

**BIO-RAD**

**Bio-Rad  
Laboratories, Inc.**

Life Science  
Group

Web site [www.bio-rad.com](http://www.bio-rad.com) USA (800) 4BIORAD Australia 02 9914 2800 Austria (01)-877 89 01 Belgium 09-385 55 11 Brazil 55 21 507 6191  
Canada (905) 712-2771 China (86-21) 63052255 Czech Republic (420) 2-4141 0532 Denmark 45 44 52-1000 Finland 358 (0)9 804 2200  
France 01 47 95 69 65 Germany 089 318 84-177 Hong Kong 852-2789-3300 India (91-124) 6398112/113/114, 6450092/93 Israel 03 951 4127  
Italy 39 02 216091 Japan 03-5811-6270 Korea 82-2-3473-4460 Latin America 305-894-5950 Mexico 52 5 534 2552 to 54  
The Netherlands 0318-540666 New Zealand 64-9-4152280 Norway 47-23-38-41-30 Poland (48) 22-8126 672 Portugal 351-21-472-7700  
Russia 7 095 721 1404 Singapore 65-2729877 South Africa 00 27 11 4428508 Spain 590 5200 Sweden 46 (0)8-55 51 27 00 Switzerland 061 717-9555  
United Kingdom 0800-181134